Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$11.46M$11.46M−13.7% vs Q3 2021 Net Income-$12.54M-$12.54MN/M vs Q3 2021 EPS Diluted-$0.23-$0.23N/M vs Q3 2021 Operating Income-$8,853,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,592,000N/M Margins · derivedOperating margin-77.2%−17.3 pt vs Q3 2021
Net margin-109.4%+0.2 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 1, 2022 · 32 d after period end